Search

Your search keyword '"Tan, Joanne"' showing total 691 results

Search Constraints

Start Over You searched for: Author "Tan, Joanne" Remove constraint Author: "Tan, Joanne"
691 results on '"Tan, Joanne"'

Search Results

157. A device to detect leakage at the patient end of total intravenous anaesthesia.

159. A Role for Chlorinated Nucleosides in the Perturbation of Macrophage Function and Promotion of Inflammation

160. The multiple roles of chemokines in the mechanisms of stent biocompatibility.

164. Abstract 3168: Methods for assessment of the “adenosine fingerprint” in clinical trials of AB928

165. Abstract 4042: Longitudinal monitoring of neoepitope-specific T cell repertoires in patient blood following cancer immunotherapy

166. Abstract 1557: Characterization of AB154, a humanized anti-TIGIT antibody, for use in combination studies

169. De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX

175. Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein

177. Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression

178. Abstract A157: Preclinical pharmacokinetic and pharmacodynamic characterization of AB680, a small-molecule CD73 inhibitor for cancer immunotherapy

179. The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit

180. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

182. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

192. Abstract 710: CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors (ICI)

193. Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control

198. VEGFR2 is activated by high‐density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemia

Catalog

Books, media, physical & digital resources